Tecentriq/atezolizumab Cost, Side effects, dosage, Uses for bladder cancer

Tecentriq/atezolizumab Cost, Side effects, dosage, Uses for bladder cancer. Tecentriq is marketed by Genentech based in San Francisco, California. The Ventana PD-L1 (SP142) assay complementary diagnostic for Tecentriq is marketed by Ventana Medical Systems, based in Tucson, Arizona.

Tecentriq acts on the PD-1/PD-L1 pathway (proteins found on the body's immune cells and some tumor cells). By blocking these co-ordinations, Tecentriq may help the body's defense system to cope with tumor cells. Tecentriq is the first FDA-affirmed PD-L1 inhibitor and the most recent in the broader class of PD-1/PD-L1 agent endorsed by the FDA in previous two years.

Tecentriq is reserved for the treatment of patients with locally progressed or metastatic urothelial carcinoma whose disease has became more severe after continuous administration of platinum-containing chemotherapy, or within range of 12 months of getting platinum-containing chemotherapy, either before (neoadjuvant) or after (adjuvant) surgical treatment. Urothelial carcinoma has high prevalence rate as compared to other type of bladder cancer. It takes place in the urinary system and spreads rapid to surrounding organs.

Tecentriq/atezolizumab Side effects

The safety and efficacy of Tecentriq were studied in a single-arm clinical trial involving 310 patients with locally advanced or metastatic urothelial carcinoma. Most common side effects that were observed during therapy are 

• Urinary tract infection,
• Decreased appetite, 
• Nausea, 
• Constipation
• Fatigue,
• Fever (pyrexia) 
• Increased risk of infection 
• Changes in immune system response
• Rashes
• Hypersensitivity

Tecentriq/atezolizumab Uses or Indications

FDA approved tecentriq/atezolizumab for the treatment of progressive or advance urothelial carcinoma. This drug is also indicated for those who have became more severe after continuous administration of platinum-containing chemotherapy, or within range of 12 months of getting platinum-containing chemotherapy, either before (neoadjuvant) or after (adjuvant) surgical treatment.

Tecentriq/atezolizumab Cost/Price

This drug is administered by your healthcare practitioner (HCP), which usually means:

• It may comes under special items category.
• You cannot fill this prescription in a regular pharmacy. Your doctor, hospital, or clinic will provide this  medication because of possible complications or other issues.
• This drug is likely to be covered under your medical benefit if you have insurance.

Tecentriq/atezolizumab Dosage

The usual dosage of tecentriq/atezolizumab is 1200 mg IV q3wk at rate 60min per infusion. This dosage frequency may be titrated in case of toxicity or increase the dosage in special instances to slow down the progression.